ASMB - Assembly Biosciences, Inc.
| Previous Close | 12.75 |
| Open | 12.72 |
| Bid | 0.00 x 800 |
| Ask | 15.25 x 800 |
| Day's Range | 12.46 - 15.00 |
| 52 Week Range | 10.58 - 38.42 |
| Volume | 599,510 |
| Avg. Volume | 285,192 |
| Market Cap | 381.049M |
| Beta (3Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.66 |
| Earnings Date | Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.40 |
- Simply Wall St.
Investors Who Bought Assembly Biosciences (NASDAQ:ASMB) Shares A Year Ago Are Now Down 67%
Investing in stocks comes with the risk that the share price will fall. And unfortunately for Assembly Biosciences...
- GlobeNewswire
Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its President and Chief Executive Officer, John McHutchison, AO, MD on August 6, 2019. The Company granted Dr. McHutchison non-qualified stock options to purchase 500,000 shares of the company’s common stock with an exercise price of $11.86 per share, the closing price of Assembly’s common stock as reported by Nasdaq on August 6, 2019.
- GlobeNewswire
Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of John McHutchison, AO, MD, as President and Chief Executive Officer effective August 6, 2019. Dr. McHutchison, who will also join Assembly’s Board of Directors, succeeds Derek Small, who co-founded Assembly Biosciences in 2014.
- Zacks
Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 34.55% and -20.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting.
- Simply Wall St.
Does The Assembly Biosciences, Inc. (NASDAQ:ASMB) Share Price Tend To Follow The Market?
If you own shares in Assembly Biosciences, Inc. (NASDAQ:ASMB) then it's worth thinking about how it contributes to the...
- GlobeNewswire
Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of dosing in a Phase 1b clinical trial to evaluate ABI-M201 (M201) in patients with mildly to moderately active ulcerative colitis (UC). M201 is Assembly’s first investigational oral live biotherapeutic product (LBP) to enter into clinical development, as part of its gastrointestinal (GI) focused collaboration with Allergan.
- GlobeNewswire
Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit
SAN FRANCISCO, June 25, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus.
- GlobeNewswire
Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonno, PhD, Executive Vice President, Chief Scientific Officer, Virology Operations, will present at the first International Association for the Study of the Liver (IASL) Congress on June 22, 2019 in Beijing.
- Insider Monkey
Here’s What Hedge Funds Think About Assembly Biosciences Inc (ASMB)
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- Simply Wall St.
Read This Before Selling Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- Zacks
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Assembly Biosciences: 1Q Earnings Snapshot
On a per-share basis, the Carmel, Indiana-based company said it had a loss of $1.05. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire
Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
SAN FRANCISCO, May 09, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus.
- Benzinga
The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...
- Zacks
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Steven J. Knox has joined the Company, as Senior Vice President, Clinical Development. Mr. Knox comes to Assembly from Gilead Sciences where he most recently served as Vice President, Clinical Research and was responsible for global development programs in inflammation and viral hepatitis.
- Motley Fool
Here's Why Assembly Biosciences Is Slipping Today
Mid-stage clinical trial results weren't what some investors were looking for.
- GlobeNewswire
Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, presented interim results from two Phase 2a clinical trials of ABI-H0731 (731), a novel antiviral in development for the treatment of chronic HBV infection. The data were presented during a late-breaker oral session on Saturday, April 13, 2019, at The International Liver Congress™(ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The late-breaker abstract was also selected for inclusion in the ‘Best of ILC’ presentation as well as for press release coverage at ILC 2019.
- GlobeNewswire
Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV.
- Motley Fool
4 Biotech Stocks With Major Catalysts in April
April's about to shower biopharma investors with important updates that could move these stocks.
- GlobeNewswire
Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
SAN FRANCISCO, March 27, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B.
- GlobeNewswire
Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit
SAN FRANCISCO, March 13, 2019 -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B.
- Simply Wall St.
If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today
It hasn't been the best quarter for Assembly Biosciences, Inc. (NASDAQ:ASMB) shareholders, since the share price has fallen 19% in that time. But that doesn't undermine the rather lovely longer-termRead More...
